Cancer has been recognized as one of the most formidable public health challenges, with estimates of nearly 12.7 million cancer cases and 7.6 million cancer deaths having occurred in 2008. Non-Hodgkin lymphoma (NHL) is the eighth most frequently diagnosed tumor type among men and the tenth among women worldwide[@b1]. Noteworthily, according to GLOBOCAN 2008 estimates, 355900 new cases and 191400 deaths might have occurred in 2008. There are a variety of different subtypes of NHL. Generally NHL is categorized into two major groups: B cell lymphomas and T cell lymphomas, with B cell lymphomas making up majority of NHL cases (about 85%). Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two major subtypes of B cell lymphomas[@b2][@b3]. North America, Australia/New Zealand, and Northern, Western, and Southern Europe with the highest incidence rates, and South-Central and Eastern Asia and the Caribbean with the lowest incidence rates[@b1]. Certain immunodefective conditions (e.g., immunosuppression, Epstein-Barr virus and human immunodeficiency virus infections) as well as occupational exposures to herbicides and chlorinated organic compounds are the main risk factors for NHL[@b1][@b4]. Moreover, deficiency of nutrients (e.g., folate) related to one-carbon metabolism is also a well-established risk factors for NHL[@b5], which has been reported to likely lead to immune responses impaired[@b6].

Folate is an important coenzyme in DNA synthesis. Methylenetetrahydrofolate reductase (MTHFR) is one of the most critical enzymes involved in folate metabolism and DNA synthesis, which catalyses the conversion of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate irreversibly[@b7]. Reduced MTHFR activity may play an inhibitory role on the 5-methyltetrahydrofolate pathway, and may lead to the accumulation of 5-methylenetetrahydrofolate, and consequentially methylation of dUMP to dTMP is decreased. Uracil can misincorporate into DNA when the methylation of dUMP to dTMP is deficient, consequentially results in DNA double-strand breaks and other anomalies, if not repaired which may lead to carcinogenesis[@b8][@b9][@b10].

The *MTHFR* gene is located at chromosome 1p36.3. Among all the identified single nucleotide polymorphisms (SNPs) in this gene, C677T (Ala222Val, rs1801133) and A1298C (Glu429Ala, rs1801131), likely associated with reduced enzyme activity, have been widely investigated in a variety of diseases, such as psychiatric disorders[@b11], congenital anomalies[@b12], colorectal cancer[@b13], and so on. Numerous studies have focused on the relationship between these two polymorphisms and NHL risk[@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39], but the conclusions remain controversial. The discrepancies among studies may be ascribed to the relatively small sample size in each investigation as well as ethnicity difference. Therefore, we performed this meta-analysis using genotype data from all eligible investigations to provide a more precise evaluation of the association of *MTHFR* C677T and A1298C polymorphisms with NHL susceptibility.

Results
=======

Study characteristics
---------------------

A total of 38 articles were initially indentified from MEDLINE and EMBASE, five more articles were indentified from the reference of retrieved studies, and ultimately, additional two articles were indentified from the CBM database ([Figure 1](#f1){ref-type="fig"}). Of them, 14 articles were excluded after title and abstract assessment, while 31 articles met the crude inclusion criteria and were further evaluated. Among these remaining 31 publications, we further excluded two studies[@b15][@b26] that were covered by other included investigations[@b20][@b24], three case-only designed studies[@b40][@b41][@b42], and one more study in which genotype frequency data in the controls for both of the C677T and A1298C polymorphisms were deviated from HWE (*P* = 0.009 for C677T and *P* = 0.040 for A1298C)[@b38]. Overall, 25 articles were included in the final meta-analysis. There were 25 articles with 7448 cases and 11146 controls for the C677T polymorphism, and 19 studies with 6173 cases and 9725 controls for the A1298C polymorphism ([Table 1](#t1){ref-type="table"}). Intriguingly, in the remaining studies, 12 and nine studies pertaining to C677T polymorphism provided detailed genotype frequency data for the DLBCL and FL subtype, respectively, while nine and eight studies regarding A1298C polymorphism provided detailed genotype data for the these two subtypes, respectively ([Supplemental Table 1](#s1){ref-type="supplementary-material"}). Sample sizes of case in the incorporated studies ranged from 28 to 1103 for C677T polymorphism and from 31 to 1124 for A1298C polymorphism.

For the C677T polymorphism, there were 19 studies conducted in Caucasians, three studies in Asians, and three studies in mixed ethnic group. Of these studies, 18 were population based (PB) and seven were hospital based (HB) designed, respectively. Furthermore, 11 studies were considered as low quality (quality socre ≤ 9), and 14 (56%) were considered as high quality (quality score \> 9). As to the A1298C polymorphism, there were 14 studies conducted in Caucasians, two studies in Asians, three studies in mixed ethnic group. While divided by the source of control, 15 studies were PB and four were HB. Among them, 6 were classified into low quality and 13 were classified into high quality. The mainly adopted genotyping methods were PCR-restriction fragment length polymorphism (12 and eight studies for C677T and A1298C, respectively) and Taqman (10 studies and eight studies for the C677T and A1298C, respectively).

Meta-analysis results
---------------------

As shown in [Table 2](#t2){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}, pooled analysis did not yield a significant association between *MTHFR* C677T polymorphism and overall NHL risk (homozygous: OR = 1.06, 95% CI = 0.93--1.20; heterozygous: OR = 0.97, 95% CI = 0.89--1.07; recessive: OR = 1.04, 95% CI = 0.95--1.15; dominant: OR = 0.99, 95% CI = 0.90--1.08 and allele comparing: OR = 1.01, 95% CI = 0.94--1.08). Next, we performed stratification analysis for the association between the C677T polymorphism variant genotypes by ethnicity, source of control, quality of studies, and tumor subtype. Stratification analysis by ethnicity revealed a statistically significantly increased NHL risk for Caucasians (homozygous: OR = 1.15, 95% CI = 1.01--1.30, and allele comparing: OR = 1.07, 95% CI = 1.01--1.13). In contrast, a significantly decreased risk of NHL was observed with the homozygous (OR = 0.70, 95% CI = 0.54--0.91) and dominant model (OR = 0.74, 95% CI = 0.59--0.91) genotypes for Asian group. Allele comparison further indicated that T variant allele is protective factor for NHL (T vs. C: OR = 0.81, 95% CI = 0.72--0.90). No significant association was found in the subgroup analysis by source of control and quality of studies. Moreover, stratification by tumor subtype demonstrated a significant increased risk of FL (homozygous: OR = 1.25, 95% CI = 1.01--1.53 and recessive: OR = 1.26, 95% CI = 1.04--1.53).

Similar to *MTHFR* C677T polymorphism, the presence of *MTHFR* A1298C polymorphism did not associate with an altered overall NHL risk (homozygous: OR = 1.21, 95% CI = 0.97--1.50; heterozygous: OR = 1.02, 95% CI = 0.95--1.09; recessive: OR = 1.21, 95% CI = 0.98--1.49; dominant: OR = 1.05, 95% CI = 0.96--1.14 and allele comparing: OR = 1.08, 95% CI = 0.98--1.18). Nevertheless, we observed a significantly increased risk of NHL for Asians (homozygous: OR = 1.54, 95% CI = 1.05--2.24; dominant: OR = 1.21, 95% CI = 1.03--1.42 and allele comparing: OR = 1.20, 95% CI = 1.05--1.38) but not other ethnic groups, when the analysis was stratified by ethnicity. No significant association was found in the remaining subgroup analyses by source of control, quality of studies and tumor subtype.

The correlation between the mRNA expression and genotypes
---------------------------------------------------------

The correlation between *MTHFR* mRNA expressions levels by the genotypes were explored for three ethnic groups (i.e., CEU, YRI and Asian) and the whole group ([Table 3](#t3){ref-type="table"}). No significant alteration in the mRNA expression levels was found for the C677T polymorphism under all the genetic models.

Interestingly, we found that C variant allele of *MTHFR* A1298C polymorphism significantly correlated with increased *MTHFR* mRNA expression levels among Caucasians (dominant model: *P* = 0.046), but decreased mRNA expression among Asians (heterozygous: *P* = 0.024 and dominant: *P* = 0.028).

Heterogeneity and sensitivity analyses
--------------------------------------

As shown in [Table 2](#t2){ref-type="table"}, substantial heterogeneities were observed among all investigations for the C677T polymorphism and NHL risk (homozygous: *P* = 0.092; heterozygous: *P* = 0.027; dominant model: *P* = 0.006 and allele comparing: *P* = 0.006), except for the recessive model (*P* = 0.465). We also observed considerable heterogeneities for the A1298C polymorphism (homozygous: *P* \< 0.001; recessive model *P* \< 0.001; dominant model: *P* = 0.064 and allele comparing: *P* \< 0.001), except for the heterozygous model (*P* = 0.471). The meta-regression analysis did not yield any significant difference between subgroup analysis. Thus, leave-one-out sensitivity analyses indicated that no single study could alter the pooled ORs obviously (data not shown).

Publication bias
----------------

The shape of the funnel plots seemed asymmetry for the C677T and A1298C polymorphisms ([Figure 3](#f3){ref-type="fig"} and [Figure 4](#f4){ref-type="fig"}), and we did not detect any significant publication bias by the Egger\'s test for C677T polymorphism (homozygous: *P* = 0.802; heterozygous: *P* = 0.462; recessive model: *P* = 0.667; dominant model: *P* = 0.568 and allele comparing: *P* = 0.761), and A1298C polymorphism (homozygous: *P* = 0.195; heterozygous: *P* = 0.767; recessive model: *P* = 0.274; dominant model: *P* = 0.312 and allele comparing: *P* = 0.152).

Discussion
==========

To our knowledge, the current meta-analysis is the largest one to investigate the association between *MTHFR* gene polymorphisms and NHL risk. Pooled analysis for the C677T polymorphism contained 25 studies with a total of 7448 NHL patients and 11146 controls; meanwhile, pooled analysis for the A1298C polymorphism encompassed 19 studies with 6173 NHL patients and 9725 controls. The meta-analysis observed no significant association between *MTHFR* C677T and A1298C polymorphisms and overall NHL risk. However, stratified analyses by ethnicity revealed that the C677T polymorphism increased NHL risk for Caucasians but decreased risk for Asians. The study of the same SNP also observed a significantly increased risk of FL, but not DLBCL, when the analysis was stratified by subtype of NHL. Moreover, the A1298C polymorphism was associated with increased risk for Asians, while no effect was observed for other ethnic groups. Interestingly, we found the *MTHFR* mRNA expression levels was slightly increased in the Asians carrying 677T alleles (*P* = 0.052), which was in accordance with our findings that C677T polymorphism was significantly associated with decreased NHL risk in the Asian group. Moreover, we also found the 1298C carriers showed significantly decreased *MTHFR* mRNA expression (*P* = 0.028), which corresponded to the evidence of association of 1298C polymorphism with increased NHL risk. Therefore, this results suggested that our findings from association studies for Asians may be biological plausible. *MTHFR* gene variants play an important role in the outcome of NHL patients. Examination of polymorphisms in the folate pathway genes might facilitate to reduce chemotherapy toxicity and improve survival by indicating when dose adjustments or alternative treatments are needed[@b40].

Folate is a critical nutrient and coenzyme involved in DNA synthesis and methylation, and folate deficiency has been reported associated with numerous malignancies[@b43]. The product of *MTHFR* gene plays an important role in the methylation of homocysteine into methionine, sequentially leading to DNA methylation[@b44]. *MTHFR* C677T and A1298C polymorphisms were widely investigated in varieties of cancers. The former genetic variation is located in exon 4, and can lead to amino acid change from alanine to valine, which was first reported in 1995. This variation was reported to associate with reduced enzyme activity from a total of 40 subjects, with the CT and TT genotypes having \~60% and \~30% of the wild-type enzyme activity, respectively[@b45]. The A1298C polymorphism is located in exon 7. It has also been reported the CC genotype carriers having \~60% of wild-type enzyme activity[@b46]. Some of the previous studies failed to found this association[@b21][@b47]. Based on the largest meta-analysis to date, none of these two polymorphisms of interest was associated with overall NHL risk. Nonetheless, stratification analyses by ethnicity detected that analyzed SNPs significantly altered the risk of developing NHL in different ethnic groups. SNPexp online tool allows us to evaluate genotypes of *MTHFR* C677T and A1298C polymorphisms and their respective *MTHFR* transcript expression levels. With this in mind, we further investigated whether the biological results are in accordance with the observed association. We performed genotype-based mRNA expression analysis using the data from 270 individual with three ethnicities. We did not find a similar trend in the mRNA expression for the Caucasians but for the Asians, which may be due to the fact that the genotype counts for the homozygous variants is relatively small.

As so far, only two meta-analyses, which were nested in case-control studies, have investigated the association of *MTHFR* C677T and/or A1298C polymorphisms and NHL susceptibility. The study carried out by Lee et al.[@b28] only studied the C677T polymorphism in Caucasians, consisting 13 studies with a total of 4245 cases and 5594 controls. The study observed increased NHL risk for T variant allele carrier in the Caucasians. Subjects with T alleles showed similarly increased risk of DLBCL and FL, in the subgroup analysis by NHL subtype. Another study included 4176 cases and 7585 controls for C677T, as well as 3648 cases and 6331 controls for A1298C polymorphism, in which no significant associations were observed for all subjects[@b37]. Some of the significant findings described above were not validated in our meta-analysis. For instance, the finding that the *MTHFR* C677T polymorphism was associated with elevated risk for DLBCL in homozygous model[@b28] could not be duplicated in our study. Such associations were no longer significant in the current meta-analysis upon the inclusion of seven more studies. We also found some significant associations that were not observed in the previous studies, one example of which was that we found the C677T polymorphism decreased NHL risk for Asians, whereas the A1298C polymorphism conferred an increased risk to them. These new findings may be ascribed to the inclusion of more investigations with much large sample size in the current meta-analysis. It was noteworthy that we found the C677T polymorphism was associated with increased NHL risk for Caucasians while with decreased NHL susceptibility for Asians. The opposite findings in different ethnic groups may be resulted from ethnicity difference as well as the number of investigations. Earlier studies indicated that diet of Western contains high heterocyclic amines and polycyclic aromatic hydrocarbons[@b48][@b49], which is relatively low in the diets of other ethnicities, which may contribute to the different effects of C677T polymorphism on cancer risk. Though we have included the latest investigations as well as publications written in Chinese, the current meta-analysis still has several limitations to be addressed. First, the sample size of cases from most eligible studies is relatively limited (\<500), except for five studies[@b21][@b23][@b28][@b29][@b32]. Among the five studies, only one study has case more than one thousand[@b29]. The relative limited cases may have compromised statistical power. Second, we only included the studies written in English and Chinese, and might miss some investigations written in other languages. Third, heterogeneity was observed under some genetic models, so the results should be interpreted cautiously. Finally, our results were derived from unadjusted estimates due to lack of the original data, such as age, gender, smoking, drinking and dietary intaking habits, occupational exposures, as well as virus infections.

In summary, this study indicated that C677T and A1298C polymorphisms in the *MTHFR* gene may be associated with NHL susceptibility, especially for Caucasians, Asians and FL. Well-designed prospective studies with large sample size should be conducted to validate our findings.

Methods
=======

Literature search strategy
--------------------------

We identified publications examined the association between *MTHFR* gene polymorphisms and NHL from MEDLINE and EMBASE using the following search items: "*MTHFR* or *methylenetetrahydrofolate reductase*", "polymorphism or variant or variation" and "non-Hodgkin lymphoma or non-Hodgkin\'s lymphoma or NHL" (the last search updated was on January 8, 2014). We also identified related publications written in Chinese from Chinese Biomedical (CBM) database using the combinations terms of "*MTHFR*", "NHL" and "polymorphism" in Chinese. Besides, we identified additional studies by searching of the references from retrieved studies manually. We only included the latest or the largest sample size studies in our final meta-analysis, if there exists more than one article published using the same subjects or overlapping data.

Inclusion and exclusion criteria
--------------------------------

Studies included in the final meta-analysis had to meet the following criteria: (1) evaluate *MTHFR* C677T and/or A1298C polymorphisms and NHL risk; (2) be a case-control study, nested case-control study or a cohort study; (3) written in English or Chinese; (4) contain SNP genotype data; (5) independent from other studies; (6) provide sufficient data to calculate odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).

The studies were excluded if genotype frequency data in the controls for *MTHFR* C677T and A1298C polymorphisms demonstrated departure from Hardy-Weinberg equilibrium (HWE) without further evidence showing that genotype distribution of other SNPs in controls followed HWE. In addition, case-only studies, case reports, conference abstract, reviews, meta-analyses and studies without detailed data were excluded.

Data extraction
---------------

Two investigators (JH and XL) independently extracted the following information from all eligible studies according to the inclusion and exclusion criteria: the first author\'s surname, year of publication, country of origin, ethnicity, cancer type and subtype (FL and DLBCL), control source (population based or hospital based), the total number of cases and controls, genotyping methods, minor allele frequency (MAF) for controls, *P* values for HWE for the control subjects and numbers of cases and controls with the CC, CT and TT genotypes for the C677T polymorphism and AA, AC and CC genotypes for the A1298C polymorphism. Any disagreement was resolved by discussion within our team numbers until consensus was reached.

Genotype based mRNA expression analysis
---------------------------------------

The genotypes data for *MTHFR* C677T and A1298C polymorphisms were available from HapMap (<http://hapmap.ncbi.nlm.nih.gov/>) for 270 subjects with three different ethnicities and their corresponding mRNA expression levels data were available from SNPexp (<http://app3.titan.uio.no/biotools/tool.php?app=snpexp>) as described previously[@b50][@b51][@b52][@b53].

Quality assessment
------------------

Two investigators assessed the quality of each investigation using the quality assessment criteria ([Supplemental Table 2](#s1){ref-type="supplementary-material"}), which was derived from previously published meta-analysis of molecular association studies[@b54]. Quality scores of studies ranged from 0 (lowest) to 15 (highest). Studies with scores ≤ 9 were categorized into low quality, while those with scores \> 9 were considered as high quality. A third investigator (JZ) would be involved if there existed any disagreement.

Statistical methods
-------------------

Crude ORs and their corresponding 95% CIs were used to evaluate the strength of associations between *MTHFR* gene polymorphisms and NHL risk. The pooled ORs were estimated for C677T polymorphism under the homozygous model (TT vs. CC), heterozygous model (CT vs. CC), recessive model (TT vs. CT + CC), dominant model (CT + TT vs. CC) and allele comparison (T vs. C). The same genetic models were also adopted for A1298C polymorphism as followed: homozygous model (CC vs. AA), heterozygous model (AC vs. AA), recessive model (CC vs. AC + AA), dominant model (AC + CC vs. AA) and allele comparison (C vs. A). Goodness-of-fit chi-square test was used to test deviation from HWE for the genotypes of controls. *P* \< 0.05 was considered significant. The Chi-square based Q-test was performed to evaluate the heterogeneity across the studies. The random-effects model[@b55] was chosen when significant heterogeneous exist (*P~heterogeneity~* \< 0.10); otherwise, fixed-effects model (the Mantel--Haenszel method)[@b56] would be adopted. Stratification and meta-regression analyses were conducted to explore the potential source of heterogeneity across studies. Furthermore, stratification analyses were conducted by ethnicity (i.e., Asians, Caucasians, and Mixed that contained more than one ethnic group), control source (hospital-based and population-based), quality score of studies (low and high), and tumor subtype (FL and DLBCL). Sensitivity analysis was performed to assess the stability of the results by sequentially excluding one study at a time and recalculating the pooled ORs and their corresponding 95% CIs. Furthermore, both the Begg\'s funnel plot[@b57] and the Egger\'s linear regression test[@b58] were performed to assess the potential publication bias. The differences in mRNA expression levels for different genotypes were evaluated by one-way ANOVA, and the mRNA expression levels trend were evaluated by General linear model. All statistical tests were performed with STATA software (version 11.0; Stata Corporation, College Station, TX) and SAS software (version 9.1; SAS Institute, Cary, NC). All the statistics were two-sided, and *P* \< 0.05 was considered as significant findings.
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![Flow diagram of selection of studies included in the current meta-analysis for the association between *MTHFR* gene polymorphisms and NHL susceptibility.](srep06159-f1){#f1}

![Forest plots of effect estimates for *MTHFR* C677T polymorphism and NHL susceptibility (TT vs. CC).\
For each study, the estimation of OR and its 95% CI are plotted with a box and a horizontal line. ◊, pooled ORs and its 95% CIs.](srep06159-f2){#f2}

![Funnel plot analysis to detect publication bias for C677T polymorphism by dominant model.\
Each point represents a separate study for the indicated association.](srep06159-f3){#f3}

![Funnel plot analysis to detect publication bias for A1298C polymorphism by dominant model.\
Each point represents a separate study for the indicated association.](srep06159-f4){#f4}

###### Characteristics of studies included in the current meta-analysis

  Surname                    Year     Country      Ethnicity   Source   Genotype method   Case   Control   MAF   HWE    Score                                    
  ------------------------- ------ -------------- ----------- -------- ----------------- ------ --------- ----- ------ ------- ----- ----- ------ ------ ------- ----
  **C677T polymorphism**                                                                                                                                         
  Gonzalez Ordonez           2000      Spain       Caucasian     HB        PCR-RFLP        21      21       5     47     92     88    20    200    0.32   0.876   6
  Lincz                      2003    Australia     Caucasian     HB        PCR-RFLP        73      58      17    148     145    133   21    299    0.29   0.198   7
  Toffoli                    2003      Italy       Caucasian     PB        PCR-RFLP        44      49      18    111     147    233   85    465    0.43   0.662   11
  Gemmati                    2004      Italy       Caucasian     PB        PCR-RFLP        60      101     39    200     78     128   51    257    0.45   0.908   10
  Linnebank                  2004      German      Caucasian     PB        PCR-RFLP        13      12       6     31     66     52    24    142    0.35   0.019   8
  Matsuo                     2004      Japan         Asian       HB        PCR-RFLP       165      122     63    350     182    230   88    500    0.41   0.301   8
  Rudd                       2004        UK        Caucasian     HB         Taqman        361      381     90    832     383    397   106   886    0.34   0.841   12
  Skibola                    2004       USA        Caucasian     PB         Taqman        122      160     52    334     288    350   84    722    0.36   0.149   14
  Lightfoot                  2005        UK        Caucasian     PB         Taqman        247      270     72    589     356    316   83    755    0.32   0.309   14
  Stanulla                   2005      German      Caucasian     PB        PCR-RFLP       207      216     64    487     184    152   43    379    0.31   0.179   9
  Chen                       2006      China         Asian       HB         Taqman         11      13       4     28     72     66    19    157    0.33   0.522   8
  Deligezer                  2006      Turkey      Caucasian     HB         Taqman         31      30       5     66     66     72    16    154    0.34   0.574   9
  Niclot                     2006      France      Caucasian     PB          DHPLC         66      86      20    172     92     88    24    204    0.33   0.674   8
  Timuragaoglu               2006      Turkey      Caucasian     PB      Realtime PCR      31      22       5     58     36     36    10     82    0.34   0.829   9
  Lee                        2007    Australia     Caucasian     PB         Taqman        253      227     74    554     256    190   57    503    0.30   0.019   11
  Lim                        2007       USA          Mixed       PB         Taqman        499      477     127   1103    443    396   86    925    0.31   0.853   15
  Siraj                      2007   Saudi Arabia   Caucasian     PB        PCR-RFLP       109      45       6    160     372    126   13    511    0.15   0.553   10
  Gra                        2008      Russia      Caucasian     HB      Hybridization     39      28       9     76     85     79    13    177    0.30   0.354   8
  Kim                        2008      Korea         Asian       PB        PCR-RFLP       223      286     75    584     540    863   297   1700   0.43   0.133   12
  Berglund                   2009      Sweden      Caucasian     PB        Illumina       154      85      24    263     241    157   32    430    0.26   0.363   10
  Ismail                     2009      Jordan      Caucasian     PB        PCR-RFLP        34      19       2     55     94     66    10    170    0.25   0.722   10
  Wang                       2009     Jamaica        Mixed       PB         Taqman        329      58       5    392     204    57     5    266    0.13   0.664   14
  Kurzwelly                  2010      German      Caucasian     PB        PCR-RFLP        78      81      26    185     96     96    20    212    0.32   0.568   10
  Weiner                     2011      Russia      Caucasian     PB         Taqman         72      60      11    143     242    198   46    486    0.30   0.553   8
  Li                         2013       USA          Mixed       PB         Taqman        202      206     72    480     236    246   82    564    0.36   0.173   15
  **A1298C polymorphism**                                                                                                                                        
  Lincz                      2003    Australia     Caucasian     HB        PCR-RFLP        64      68      13    145     124    139   31    294    0.34   0.385   7
  Toffoli                    2003      Italy       Caucasian     PB        PCR-RFLP        54      44      13    111     200    222   43    465    0.33   0.094   11
  Gemmati                    2004      Italy       Caucasian     PB        PCR-RFLP        96      90      14    200     126    110   21    257    0.30   0.659   10
  Linnebank                  2004      German      Caucasian     PB        PCR-RFLP        16      12       3     31     69     54    19    142    0.32   0.116   9
  Matsuo                     2004      Japan         Asian       HB        PCR-RFLP       209      122     19    350     327    150   23    500    0.20   0.282   8
  Rudd                       2004        UK        Caucasian     HB         Taqman        397      363     72    832     412    389   85    886    0.32   0.622   12
  Skibola                    2004       USA        Caucasian     PB         Taqman        178      128     27    333     341    310   71    722    0.31   0.964   14
  Lightfoot                  2005        UK        Caucasian     PB         Taqman        288      250     51    589     347    331   77    755    0.32   0.882   14
  Niclot                     2006      France      Caucasian     PB          DHPLC         79      76      17    172     102    81    15    198    0.28   0.844   8
  Lim                        2007       USA          Mixed       PB         Taqman        540      480     104   1124    461    393   81    935    0.30   0.831   15
  Siraj                      2007   Saudi Arabia   Caucasian     PB        PCR-RFLP        38      40      35    113     239    220   52    511    0.32   0.896   10
  Gra                        2008      Russia      Caucasian     HB      Hybridization     36      30      10     76     81     82    14    177    0.31   0.278   8
  Kim                        2008      Korea         Asian       PB         Taqman        372      182     29    583    1147    500   53    1700   0.18   0.868   12
  Berglund                   2009      Sweden      Caucasian     PB        Illumina       116      121     25    262     214    196   39    449    0.31   0.533   10
  Ismail                     2009      Jordan      Caucasian     PB        PCR-RFLP        20      23      12     55     76     81    13    170    0.31   0.172   10
  Wang                       2009     Jamaica        Mixed       PB         Taqman        277      98      15    390     201    65     9    275    0.15   0.198   14
  Kurzwelly                  2010      German      Caucasian     PB        PCR-RFLP        72      96      17    185     106    89    17    212    0.29   0.779   10
  Weiner                     2011      Russia      Caucasian     PB         Taqman         59      52      22    133     232    215   56    503    0.33   0.562   8
  Li                         2013       USA          Mixed       PB         Taqman        246      203     40    489     265    250   59    574    0.32   0.997   15

HB, Hospital based; PB, Population based; PCR-RFLP, Polymorphism chain reaction-restriction fragment length polymorphism; DHPLC, Denaturing high performance liquid chromatography; MAF, Minor allele frequency; HWE, Hardy-Weinberg equilibrium.

###### Meta-analysis of the association between *MTHFR* C677T and A1298C polymorphisms and cancer risk

  Variables             No. of study     Sample          Homozygous           Heterozygous         Recessive       Dominant     Allele Comparing                                                                       
  -------------------- -------------- ------------ ----------------------- ------------------ ------------------- ---------- ----------------------- --------- ----------------------- ------- ----------------------- ---------
  C677T (rs1801133)      TT vs. CC     CT vs. CC      TT vs. (CT + CC)      (CT + TT) vs. CC        T vs. C                                                                                                            
  All                        25        7448/11146     1.06 (0.93--1.20)          0.092         0.97 (0.89--1.07)    0.027       1.04 (0.95--1.15)      0.465      0.99 (0.90--1.08)     0.006     1.01 (0.94--1.08)      0.006
  Ethnicity                                                                                                                                                                                                            
  Caucasian                  19        4511/7034    **1.15 (1.01--1.30)**        0.720         1.06 (0.97--1.15)    0.639       1.11 (0.98--1.25)      0.838      1.08 (0.99--1.16)     0.546   **1.07 (1.01--1.13)**    0.556
  Asian                      3          962/2357    **0.70 (0.54--0.91)**        0.320         0.74 (0.55--1.01)    0.108       0.81 (0.66--1.00)      0.187    **0.74 (0.59--0.91)**   0.238   **0.81 (0.72--0.90)**    0.391
  Mixed                      3         1975/1755      1.16 (0.92--1.46)          0.364         0.92 (0.71--1.19)    0.067       1.15 (0.93--1.43)      0.473      0.93 (0.71--1.22)     0.034     0.96 (0.76--1.20)      0.023
  Source of control                                                                                                                                                                                                    
  PB                         18        5901/8773      1.08 (0.92--1.27)          0.050         1.01 (0.92--1.12)    0.086       1.05 (0.94--1.17)      0.329      1.02 (0.92--1.13)     0.010     1.02 (0.94--1.11)      0.003
  HB                         7         1547/2373      0.95 (0.77--1.17)          0.552         0.86 (0.69--1.06)    0.120       1.02 (0.84--1.25)      0.560      0.89 (0.75--1.05)     0.244     0.95 (0.86--1.04)      0.571
  Score                                                                                                                                                                                                                
  Low                        11        1606/2780      1.04 (0.85--1.28)          0.650         0.95 (0.78--1.16)    0.048       1.09 (0.89--1.32)      0.876      0.97 (0.81--1.17)     0.078     1.00 (0.90--1.12)      0.319
  High                       14        5842/8366      1.06 (0.89--1.27)          0.018         0.99 (0.90--1.09)    0.092       1.03 (0.93--1.15)      0.139      1.00 (0.89--1.11)     0.010     1.01 (0.92--1.11)      0.001
  Subtype                                                                                                                                                                                                              
  DLBCL                      12        1966/7271      1.03 (0.81--1.30)          0.047         0.94 (0.78--1.13)    0.002       1.02 (0.88--1.20)      0.196      0.96 (0.80--1.14)     0.002     1.00 (0.89--1.13)      0.011
  FL                         9         1251/4508    **1.25 (1.01--1.53)**        0.501         0.93 (0.75--1.14)    0.034     **1.26 (1.04--1.53)**    0.645      0.98 (0.81--1.19)     0.049     1.05 (0.93--1.19)      0.164
  A1298C (rs1801131)     CC vs. AA     AC vs. AA      CC vs. (AC + AA)      (AC + CC) vs. AA        C vs. A                                                                                                            
  All                        19        6173/9725      1.21 (0.97--1.50)         \<0.001        1.02 (0.95--1.09)    0.471       1.21 (0.98--1.49)     \<0.001     1.05 (0.96--1.14)     0.064     1.08 (0.98--1.18)     \<0.001
  Ethnicity                                                                                                                                                                                                            
  Caucasian                  14        3237/5741      1.24 (0.93--1.67)         \<0.001        0.98 (0.89--1.08)    0.490       1.25 (0.94--1.66)     \<0.001     1.03 (0.92--1.17)     0.075     1.09 (0.96--1.23)     \<0.001
  Asian                      2          933/2200    **1.54 (1.05--2.24)**        0.506         1.17 (0.99--1.39)    0.494       1.46 (1.00--2.11)      0.430    **1.21 (1.03--1.42)**   0.646   **1.20 (1.05--1.38)**    0.908
  Mixed                      3         2003/1784      0.96 (0.72--1.29)          0.293         1.00 (0.87--1.14)    0.471       0.98 (0.77--1.24)      0.426      0.99 (0.85--1.15)     0.291     0.99 (0.86--1.14)      0.199
  Source of control                                                                                                                                                                                                    
  PB                         15        4770/7868      1.26 (0.97--1.64)         \<0.001        1.01 (0.93--1.10)    0.400       1.25 (0.97--1.61)     \<0.001     1.06 (0.95--1.18)     0.039     1.09 (0.98--1.22)     \<0.001
  HB                         4         1403/1857      0.98 (0.75--1.28)          0.467         1.02 (0.88--1.19)    0.381       0.99 (0.76--1.27)      0.443      1.02 (0.88--1.19)     0.356     1.02 (0.90--1.15)      0.319
  Score                                                                                                                                                                                                                
  Low                        6          907/1814      1.27 (0.94--1.71)          0.669         1.08 (0.91--1.29)    0.680       1.26 (0.94--1.68)      0.612      1.11 (0.94--1.31)     0.732     1.12 (0.98--1.27)      0.673
  High                       13        5266/7911      1.21 (0.92--1.59)         \<0.001        1.00 (0.93--1.08)    0.299       1.21 (0.93--1.57)     \<0.001     1.04 (0.93--1.16)     0.019     1.08 (0.96--1.21)     \<0.001
  Subtype                                                                                                                                                                                                              
  DLBCL                      9         1624/6331      1.23 (0.84--1.79)          0.002         1.02 (0.91--1.15)    0.515       1.25 (0.86--1.81)      0.001      1.06 (0.94--1.18)     0.127     1.09 (0.92--1.28)      0.001
  FL                         8         1039/4023      1.26 (0.88--1.79)          0.081         1.04 (0.90--1.21)    0.403       1.23 (0.90--1.67)      0.153      1.07 (0.93--1.23)     0.147     1.10 (0.93--1.30)      0.036
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HB, Hospital based; PB, Population based; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma.

###### *MTHFR* mRNA expression by the genotypes of SNPs, using data from the HapMap[a](#t3-fn1){ref-type="fn"}

  Population                          C667T (rs1801133)   A1298C (rs1801131)                                                                           
  ---------------------------------- ------------------- -------------------- ------------- ------- ------- ---------- ----- ------------- ----------- -------
  CEU                                        CC                   48           6.14 ± 0.10           0.904      AA      41    6.12 ± 0.09               0.139
                                             CT                   37           6.14 ± 0.09   0.924              AC      36    6.15 ± 0.10     0.069        
                                             TT                   5            6.12 ± 0.09   0.685              CC      13    6.16 ± 0.09     0.163        
                                          Dominant                42           6.14 ± 0.09   0.983           Dominant   49    6.15 ± 0.09   **0.046**      
  YRI[d](#t3-fn4){ref-type="fn"}             CC                   70           6.20 ± 0.08           0.329      AA      71    6.20 ± 0.07               0.197
                                             CT                   19           6.19 ± 0.06   0.651              AC      17    6.19 ± 0.09     0.504        
                                             TT                   1               6.09       0.171              CC       1       6.07         0.074        
                                          Dominant                20           6.19 ± 0.06   0.470           Dominant   18    6.18 ± 0.09     0.317        
  Asian[d](#t3-fn4){ref-type="fn"}           CC                   30           6.18 ± 0.08           0.116      AA      59    6.22 ± 0.10               0.074
                                             CT                   40           6.21 ± 0.09   0.120              AC      28    6.17 ± 0.09   **0.024**      
                                             TT                   19           6.23 ± 0.11   0.052              CC       3    6.20 ± 0.06     0.814        
                                          Dominant                59           6.22 ± 0.10   0.057           Dominant   31    6.17 ± 0.08   **0.028**      
  All[d](#t3-fn4){ref-type="fn"}             CC                  148           6.17 ± 0.09           0.360      AA      171   6.19 ± 0.09               0.186
                                             CT                   96           6.18 ± 0.09   0.732              AC      81    6.17 ± 0.09     0.107        
                                             TT                   25           6.20 ± 0.12   0.156              CC      17    6.16 ± 0.09     0.261        
                                          Dominant               121           6.18 ± 0.10   0.422           Dominant   98    6.16 ± 0.09     0.069        

^a^Genotyping data and mRNA expression levels for *MTHFR* by genotypes were obtained from the HapMap phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals.

^b^Two-side Student\'s *t* test within the stratum.

^c^*P* values for the trend test of *MTHFR* mRNA expression among 3 genotypes for each SNP from a general linear model.

^d^There were missing data because genotyping data were not available.
